GU Cancers 2023 | Rationale and study design of retrospective study on ICIs in penile cancer

Talal El Zarif, MD, Dana-Farber Cancer Institute, Boston, MA, explains the rationale and study design of a retrospective study conducted by the Global Society of Rare Genitourinary Tumors on the safety and efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced penile cancer. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.